Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
Thousand Oaks, Calif., South San Francisco, Calif., and Suresnes, France (ots/PRNewswire) - - Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events - Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death - Results Will Be Presented in Late Breaking ...
SURESNES, France and MONTRÉAL, November 8, 2011 (ots/PRNewswire) - Les Laboratoires Servier, France (Servier) and Prognomix Inc., Canada (Prognomix) announced today that they have entered into a research and development agreement aimed at identifying novel targets as part of programs meant to develop innovative type 2 diabetes and metabolic disease treatment. This ...